HomeENGLISH MAGAZINEStem cell technology: tropoelastin' the niche for better growth

Stem cell technology: tropoelastin’ the niche for better growth

Stem cells are vital for therapeutic treatments to repair and build human tissue like bone marrow, skin and muscles. Stem cells are increasingly being used as cell therapies for a range of diseases that cannot be reliably treated by conventional medicine including skeletal tissue injuries, heart attacks, degenerative diseases and organ failure. Unfortunately, a lack of supply is hindering widespread use of such cell therapies. Researchers are constantly looking for ways to make stem cells work better, with worldwide demand for the cells far outstripping supply.

Now researchers have discovered a way to generate more stem cells cheaply and quickly, using tropoelastin – a protein that gives living tissues the ability to stretch and retract. Published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS), co-authors Dr Giselle Yeo and Professor Anthony Weiss – from the University of Sydney’s Charles Perkins Centre, School of Life and Environmental Sciences and Bosch Institute – said the study describes a new and cost-effective method of growing and recruiting mesenchymal stem cells (MSCs) rapidly and efficiently. Tropoelastin is a key component of MeTro, the groundbreaking ‘squirtable’ elastic surgical glue that can seal wounds in 60 seconds when exposed to UV light, developed by Professor Weiss in conjunction with researchers in the United States. Professor Weiss won the Eureka Prize for Innovation in Medical Research for his development and commercialisation of tropoelastin protein biomaterials.

Using human stem cells from donors, the researchers found that when small amounts of tropoelastin were applied it encouraged more cells to be produced, creating a better environment for growth compared to other commonly used proteins for stem cell cultures. Entering into details, the Authors found that tropoelastin alone drives MSC proliferation and phenotypic maintenance, akin to the synergistic effects of mitogenic growth factors such as basic fibroblast growth factor (bFGF) and insulin-like growth factor 1 (IGF-1). In addition, tropoelastin functionally surpasses these growth factors, as well as fibronectin, in allowing substantial media serum reduction without loss of proliferative potential. Researchers furtherly demonstrate that tropoelastin elicits strong cell-attractive and mitogenic esponses, both as an immobilized substrate and as a soluble additive, via direct interactions with cell surface integrins αvβ3 and αvβ5. Stem cells need a home to live and grow, and basically scientists created a nice environment for them to settle.

Professor Weiss explained thoroughly: “Our discovery that tropoelastin dramatically promotes stem cell expansion and recruitment, and reliably preserves their ability to develop into different types of cells, points to new ways of cost-effectively and efficiently growing these stem cells to address the increasing global demand. Making stems cells requires a process a bit like cooking soup – the more complex the culture or ‘soup’, the more difficult it is to control the growth of the cells and the more expensive it is to make.  This technique simplifies the ‘soup’ – tropoelastin makes the process to grow stem cells simpler, and cheaper. Moreover, tropoelastin also encourages other stem cells to join the ‘soup’ – further increasing their rate of growth. Such technologies can help significantly lower the currently prohibitive cost of many cell therapies. The next stage of research would be to test the efficacy of tropoelastin inside the body. We expect that once these stem cells are inside a living body they will actually help trigger repair, encouraging other cells to come to the damaged area and supporting the body to repair itself”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Yeo GC, Weiss AS. Proc Natl Acad Sci U S A. 2019 Jan 18.

Shakouri-Motlagh A et al. Acta Biomater. 2017 Jun; 55:1-12.

Feng J et al. Proc Natl Acad Sci. 2011; 108(16):6503-6508.

Wise SG et al. Adv Protein Chem Struct Biol. 2009; 78:1-24.

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -